GALDERMA GROUP AG (GALDY) — Quality & forensics
As of 2026-09-24 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 27
- Quality 58
- Growth 77
- Balance sheet 52
- Cash quality 56
- Capital allocation 52
- Momentum 40
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the GALDY chart & overview
FAQ · from the current data · as of 2026-09-24
Quick answers
What is GALDERMA GROUP AG's Closelook quality reading?
The composite reads 54/100 across 7 modules, as of 2026-09-24: valuation 27, quality 58, growth 77, balance sheet 52, cash quality 56, capital allocation 52, momentum 40. Closelook scores are research diary readings, not ratings or investment advice.
What is GALDERMA GROUP AG's Altman Z-Score?
6.49, which sits in the safe zone (above 2.99) as of 2026-09-24. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is GALDERMA GROUP AG's Piotroski F-Score?
7 of 9, as of 2026-09-24. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does GALDERMA GROUP AG's Beneish M-Score indicate?
-2.52 — below the −1.78 manipulation-risk threshold, as of 2026-09-24. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelook universe
then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- ROVI.MC Laboratorios Farmaceuticos ROVIindustry
- LNTH Lantheus Holdings Incindustry
- KNSA Kiniksa Pharmaceuticals Ltdindustry
- AMRX Amneal Pharmaceuticals, Inc. Class A Common Stockindustry
- BHC.TO Bausch Health Companies Incindustry
- ALM.MC Almirall S.A.industry
- PRGO Perrigo Company PLCindustry
- HCM.L HUTCHMED China Ltdindustry
- VTRS Viatris Incindustry
- RDY Dr. Reddy’s Laboratories Ltd ADRindustry
- DMP.DE Dermapharm Holding SEindustry
- ZTS Zoetis Incindustry
- ELAN Elanco Animal Healthindustry
- UTHR United Therapeutics Corporationindustry
- NBIX Neurocrine Biosciences Incindustry
- HALO Halozyme Therapeutics Incsector
- DXCM DexCom Incsector
- ARGX argenx NV ADRsector
- ONC BeiGene, Ltd.sector
- TWST Twist Bioscience Corpsector